The UK and US have reached a significant bilateral deal that will guarantee zero duties on UK medicine exports entering the American market.
The Terms of the Pact
As part of the deal, the UK has pledged to raise spending on pharmaceuticals through the public health system. This pledge ensures that import taxes on these key goods will remain at nothing for a duration of three years.
This agreement comes after previous warnings to dramatically increase duties on patented pharmaceutical imports, with figures discussed reaching one hundred percent.
"This deal with the United Kingdom strengthens the global environment for innovative medicines and introduces long-overdue fairness to U.S.–U.K. pharmaceutical trade," a statement said.
Trade Impact
Drugs are one of the the United Kingdom's largest exports to the United States, which is by far the primary destination for large UK drugmakers.
Trade data show that in the year to the end of the third quarter, the UK sold drugs valued at over eleven billion pounds to the US. This value accounted for 17.4% of British export trade in that timeframe.
"This deal safeguards jobs, increases investment and sets the stage for the UK to emerge as a global hub for biotech and pharma," the Business and Trade Secretary stated.
Specific NHS Changes
The agreement involves several key pledges from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to double overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The percentage manufacturers must refund to the NHS to stay within budget will be limited at fifteen percent. Last year, repayments exceeded twenty percent.
Broader Context
The deal takes place against a protracted dispute between the drug companies and the British authorities over spending levels and regulatory access.
This friction were heightened by arguments that US patients were charged significantly more for the identical medicines than patients in the other developed nations.
Over the last 18 months, several large drug company projects in the UK have been delayed or cancelled, while substantial expansions have been announced toward US facilities.
The Science Minister acknowledged that the NHS needed to spend more on medicines, noting that its expenditure on drugs had decreased as a percentage of its total funding over the previous ten-year period.
